Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07235280 · ClinicalTrials.gov registry record · Early Phase 1
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
A Early Phase 1 study of Lung Cancer and Lung Adenocarcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT07235280 is a Early Phase 1 study of Lung Cancer and Lung Adenocarcinoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 48 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07235280, a Early Phase 1 study of Lung Cancer and Lung Adenocarcinoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the Food and Drug Administration (FDA) for the treatment of diabetes and heart failure. It is an SGLT2 inhibitor. Stage I lung adenocarcinomas express significantly higher levels of the SGLT2 protein than other stages, and research suggests that SGLT2 inhibition improves lung cancer outcomes in patients with diabetes. In this study, dapagliflozin is being used off-label, which means it is being used for a condition that it was not originally approved for by the FDA. The investigational study drug is a neoadjuvant treatment, meaning the drug is given before surgery to try and help make the surgery more effective.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- PROCEDURE Computed Tomography Assisted Biopsy
- DRUG Dapagliflozin Propanediol
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2029-06-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07235280
The ClinicalTrials.gov registry entry for NCT07235280 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT07235280 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07235280 about?
NCT07235280 is a clinical study titled "Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma". This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the Food and Drug Administration (FDA) for the treatment of diabetes and heart failure. It is an SGLT2 inhibitor. Stage I lun...
What is the current status of trial NCT07235280?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2025-12-02. Estimated completion is 2029-06-29.
What conditions does trial NCT07235280 study?
This clinical trial studies the following conditions: Lung Cancer, Lung Adenocarcinoma, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8.
What interventions are being tested in trial NCT07235280?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Computed Tomography Assisted Biopsy (PROCEDURE), Dapagliflozin Propanediol (DRUG).
Who is sponsoring clinical trial NCT07235280?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07235280 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
RECRUITING · Early Phase 1
-
Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)
ACTIVE NOT RECRUITING · Early Phase 1
-
Microdevice for Evaluating Drug Response in Site in Lung Lesions
COMPLETED · Early Phase 1
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.